About 148 results

ALLMedicine™ Coronary Drug-eluting Stent Center

Research & Reviews  52 results

Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantati...
Circulation Wu H, Xu L et. al.

Nov 7th, 2022 - Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care after percutaneous coronary intervention. However, some adverse noncardiac effects limited the use of aspirin in clinical practice. Thus, evaluation...

Combined Analysis of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-...
Circulation. Cardiovascular Interventions; Scheller B, Mangner N et. al.

Sep 21st, 2022 - Paclitaxel-coated balloons (PCBs) are a preferred treatment option for coronary in-stent restenosis. To date, data from randomized trials of alternative drug coatings are lacking. The aim of the randomized Malaysian and German-Swiss randomized tri...

Clinical Outcome of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent Imp...
Cardiovascular Drugs and Therapy; Zhang Y, Wu Z et. al.

Aug 6th, 2022 - In-stent chronic total occlusion (IS-CTO) represents a unique challenge for percutaneous coronary intervention. Whether the optimal treatment for IS-CTO is angioplasty with paclitaxel-coated balloons (PCBs) or repeat stenting with drug-eluting ste...

Differential Proteomic Profiles of Coronary Serum Exosomes in Acute Myocardial Infarcti...
Cardiovascular Drugs and Therapy; Wang W, Zhao Y et. al.

Jul 14th, 2022 - Delayed re-endothelialization after coronary drug-eluting stent implantation is associated with an increased incidence of late in-stent thrombosis. Serum exosomes exhibit controversial effects on promoting endothelialization. This study aimed to c...

Coronary Drug-Eluting Stent

Jun 20th, 2022 - Products Drug-eluting stents (DES) are a standard metallic coronary stent with a polymer coating and an antiproliferative drug, which allows drug elution into the coronary wall for weeks to months after stent implantation. Category Drug-eluting st...

see more →

Clinicaltrials.gov  4 results

Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon

Aug 27th, 2021 - The aim of the study is to investigate the non-inferiority of the new sirolimus-coated balloon catheters in comparison to the paclitaxel-coated SQP with regard to acute tolerance, safety and efficacy in coronary DES in-stent restenosis. Patient po...

Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial

Dec 10th, 2015 - Sirolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan. Everolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in the first quarter of 2010 by the Japanese Ministry of Health, Lab...

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial

Dec 10th, 2015 - Everolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan. Biolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in 2011 by the Japanese Ministry of Health, Labor and Welfare. It has...

ProStent Coronary Drug-Eluting Stent

Apr 30th, 2009 - A single blind, multi-center, randomized study is preformed to compare ProStent drug-eluting stents with Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd. to evaluate the safety and efficacy of ProStent drug-eluting stent in...

see more →

News  3 results

BIOFLOW V: Orsiro outperforms Xience stent
Susan London

Nov 5th, 2018 - SAN DIEGO – Seemingly nuanced differences between drug-eluting stents can translate to substantial differences in clinical outcomes longer term, updated results of the BIOFLOW V randomized trial reported at the Transcatheter Cardiovascular Therape.

Reigning Coronary DES King Matches Its Predecessor
Mitchel L. Zoler, PhD

Aug 30th, 2011 - PARIS – The current master of the coronary drug-eluting stent universe, the everolimus-eluting stent, finally proved itself fully worthy of its position, matching the efficacy and safety performance of its predecessor, the sirolimus-eluting corona.

Coronary Drug-Eluting Stent Safety Diminishes Over Time

Dec 18th, 2008 - Action Points Explain to interested patients that this study suggests that both drug-eluting and bare-metal stents have good long-term safety profiles. Explain to patients who ask that a number of factors influence the choice of stent type. Explai...

see more →